Mizuho Upgrades Arcutis Biotherapeutics to Buy, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has upgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from Neutral to Buy and increased the price target from $4 to $8, indicating a more positive outlook on the company's stock.

January 03, 2024 | 9:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics has been upgraded by Mizuho from Neutral to Buy, with the price target raised from $4 to $8, suggesting a bullish view on the stock's future performance.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they often reflect an improved outlook on the company's future earnings potential and financial health. The doubling of the price target from $4 to $8 is a significant change that could influence investor sentiment and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100